Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
Noosa News20 hours agoRocky waters ahead for Brisbane 2032’s Olympic rowing plan
-
Noosa News24 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years
-
Noosa News18 hours agoMissing man, Maroochydore – Queensland Police News
-
General21 hours agoEV buses join Perth’s wider suburban network, ‘milestone’ for diesel phase-out